Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

A real-world trial in 3,000+ participants currently enrolling participants with type 2 diabetes
Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users
The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins
Amalgam Rx receives FDA clearance for basal insulin dosing app, iSage Rx; available with a prescription to adjust Lantus, Levemir, Toujeo, Tresiba, and Basaglar
How to get cheaper drugs, find discount programs, get free care in clinical trials, and more
Novo Nordisk’s once-weekly injectable GLP-1 for type 2 diabetes recommended for approval, given strong A1c reduction and weight loss
Includes insulin dose advisor software; plus, a new Novo Nordisk connected Echo insulin pen to debut in Europe later this year
An FDA advisory panel voted 17-2 to expand the drug label for type 2 diabetes drug Victoza to reflect a 13% reduction in overall heart risk and 22% reduction in heart-...
How I avoid highs, prevent lows, and stop blood sugar frustration during exercise
Easy-to-use Bydureon pen cuts down on the hassle of once-weekly injections by offering convenient mixing, a hidden needle, and more​
A basal insulin and GLP-1 agonist combo becomes available in the US and receives approval in Europe
The latest evidence on Saxenda shows that three years of treatment with the drug lowers risk for type 2 diabetes by an impressive 79%
The U.S. Food and Drug Administration (FDA) has approved the once-weekly injectable Ozempic (semaglutide) for use in type 2 diabetes.
Admelog is Sanofi’s version of Humalog (insulin lispro). New prescription savings card is for both Admelog and Lantus for people who would otherwise need to pay full...
The diaTribe Foundation and TCOYD hosted a panel discussion at the ADA 78 th Scientific Sessions in Orlando, Florida; read about insights on how to improve diabetes care
Phase 3 clinical trial currently recruiting 400 adults with type 2 diabetes
Two new studies will investigate whether SGLT-2 inhibitor Farxiga impacts heart failure in people with type 2 diabetes and prediabetes
Two new studies will investigate whether SGLT-2 inhibitor Jardiance impacts heart failure in people with and without diabetes. Jardiance is already approved to lower A1C...
Adults with type 1 and type 2 can now choose Fiasp, which can be taken up to 20 minutes after starting a meal and still be effective
ADA is around the corner, and there’s going to be exciting updates on diabetes drugs and therapy, devices, big picture questions, #beyondA1C, and advocacy; stay tuned!